98%
921
2 minutes
20
Undifferentiated melanoma, defined as melanoma that has lost all usual phenotypic and immunohistochemical characteristics of conventional melanoma, can pose significant diagnostic challenges. Molecular studies have advanced our understanding of undifferentiated melanoma by demonstrating that a subset of these tumors harbors known melanoma driver alterations in genes such as BRAF, NRAS, and NF1. However, there is a paucity of data describing genetic alterations that may distinguish undifferentiated melanoma from conventional melanoma. In this study, we directly compared the genomic profiles of undifferentiated melanoma to a cohort of conventional melanomas, including 14 undifferentiated melanoma cases (comprised of 2 primary cases, 2 cutaneous recurrences, and 10 metastases) and a cohort of 127 conventional melanomas including primary, recurrent, and metastatic cases. Targeted sequencing of 447 cancer-associated genes was performed, including identification of mutations and copy number alterations. NRAS was the most frequent melanoma driver in undifferentiated melanoma (8/14 cases, 57%), although notably, only 1 undifferentiated melanoma harbored an NRAS Q61R mutation. Compared with the conventional melanoma cohort, undifferentiated melanoma demonstrated statistically significant enrichment of pathogenic activating RAC1 mutations (6/14 total cases, 43%), including P29S (4/6 cases), P29L (1/6 cases), and D11E (1/6 cases). In addition to providing insight into the molecular pathogenesis of undifferentiated melanoma, these findings also suggest that RAS Q61R immunohistochemistry may have limited utility for its diagnosis. The presence of recurrent RAC1 mutations in undifferentiated melanoma is also notable as these alterations may contribute to mitogen-activated protein kinase pathway-targeted therapy resistance. Furthermore, the RAC1 alterations identified in this cohort have been shown to drive a melanocytic to mesenchymal switch in melanocytes, offering a possible explanation for the undifferentiated phenotype of these melanomas.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320567 | PMC |
http://dx.doi.org/10.1016/j.modpat.2024.100626 | DOI Listing |
Curr Treat Options Oncol
September 2025
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
Undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) are among the most common adult soft tissue sarcoma (STS) subtypes. Due to their high genetic complexity, heterogeneity, and lack of specific genetic alterations, no consistent molecular targets for targeted therapy have been identified for UPS and MFS. Recently, immune checkpoint inhibition (ICI) has emerged as a promising treatment modality for UPS and MFS.
View Article and Find Full Text PDFJ Oral Pathol Med
August 2025
Department of Pathology, Faculty of Medical Sciences, University of Campinas (UNICAMP), São Paulo, Brazil.
Background: Melanoma affects skin and mucosa and can be particularly aggressive when the lesion is an advanced cutaneous tumor or located in the sinonasal or oral mucosa. Reprogramming of energy metabolism has been defined as a hallmark of cancer; so this study aimed to verify the expression of proteins related to metabolism and cellular proliferation.
Methods: Immunohistochemical analysis with antibodies adipophilin, FASN, GLUT-1, HIF-1α, and Ki-67 was performed in a series of 28 sinonasal melanomas (SM), 16 oral melanomas (OM), and 39 cutaneous melanomas (CM).
Laryngoscope
August 2025
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Canada.
Objectives: Sinonasal cancers (SNC) are heterogeneous diseases with different clinical behavior. We aimed to identify prognostic factors in non-metastatic (M0)-SNC.
Methods: Electronic health records from M0-SNC patients treated with definitive surgery ± postoperative radiotherapy or chemoradiotherapy at two tertiary institutions were reviewed.
J Cutan Pathol
August 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Background: Differentiating metastatic melanoma from histologic mimics such as malignant gastrointestinal neuroectodermal tumor (GNET), malignant melanotic nerve sheath tumor (MMNST), and epithelioid malignant peripheral nerve sheath tumor (EMPNST) poses significant diagnostic challenges due to overlapping morphology and immunophenotypes. PRAME is a novel immunohistochemical marker increasingly used to distinguish melanoma from its mimics, but remains underexplored in these rare tumor types.
Methods: PRAME immunohistochemistry was performed on four GNETs, seven MMNSTs, 10 EMPNSTs, 16 metastatic melanomas (including eight undifferentiated melanomas), and two MITF-rearranged melanocytic tumors.
Cureus
July 2025
Digestive and General Surgery, Shimane University Faculty of Medicine, Izumo, JPN.
BCL6 corepressor (BCOR)-rearrangement sarcoma, an undifferentiated round cell sarcoma, is rare, and its pathophysiology is diverse. A 14-year-old girl presented with a tumor in the left kidney with invasion of the left iliopsoas muscle, left renal vein, and inferior vena cava. An immunohistochemical analysis of the tumor biopsy specimen was positive for BCOR, but no BCOR gene aberrations were detected.
View Article and Find Full Text PDF